NEW YORK ( TheStreet) -- CHANGE IN RATINGS
Acorda Therapeutics (ACOR) downgraded at Leerink from Outperform to Market Perform. Valuation call, as potential risks lay ahead.
Baker Hughes (BHI - Get Report) reinstated at BofA/Merrill. BHI coverage reinstated with a Buy rating and $61 price target. HBI has above average exposure to higher growth, early cycle product service lines.Cameron International (CAM) reinstated at BofA/Merrill. CAM coverage reinstated with a Buy rating and $56 price target. Upside from integration of NATCO acquisition, Bank of America/Merrill Lynch said. Core Labs (CLB) initiated at BofA/Merrill. CLB coverage initiated with a Buy rating and $136 price target. Buy based on continuation of share buybacks, valuation, and earnings acceleration. Citrix Systems (CTXS) rated new Neutral at UBS. Coverage of CTXS was started with a Neutral rating. $47 price target. Stock is already pricing in increased IT spending. Deere (DE - Get Report) upgraded at JP Morgan from Neutral to Overweight. $65 price target. Seeing signs of a recovery in multiple areas of equipment. Deere (DE - Get Report) estimates, target increased at UBS. Shares of DE now seen reaching $61. Estimates also raised, because of higher expected agriculture demand. Neutral rating. Dril-Quip (DRQ) initiated at BofA/Merrill. DRQ coverage initiated with a Buy rating and $68 price target. Recent capacity expansion is driving revenue growth. FMC Technologies (FTI) reinstated at BofA/Merrill with an Underperform rating and $65 price target. Not many growth catalysts and poor valuation, Bank of America/Merrill Lynch said.